MARKET

BIIB

BIIB

Biogen Inc
NASDAQ
177.08
+0.75
+0.43%
After Hours: 177.08 0 0.00% 16:15 12/26 EST
OPEN
175.30
PREV CLOSE
176.33
HIGH
177.19
LOW
175.00
VOLUME
687.40K
TURNOVER
--
52 WEEK HIGH
185.17
52 WEEK LOW
110.04
MARKET CAP
25.98B
P/E (TTM)
16.15
1D
5D
1M
3M
1Y
5Y
1D
Eli Lilly: Mr. Market Finally Woke Up, But I'm Not Out Yet (Rating Downgrade)
Seeking Alpha · 3d ago
Is Biogen Inc Gaining or Losing Market Support?
Benzinga · 3d ago
Biogen to Microsoft: 4 Stocks Morningstar Likes for 2026
TipRanks · 3d ago
JAMA Neurology Data Shows Meaningful Effects With Biogen's QALSODY In Long-Term Results
NASDAQ · 4d ago
Biogen (BIIB): Reassessing Valuation After New QALSODY Data, Pipeline Progress and Renewed Growth Optimism
Simply Wall St · 4d ago
Biogen announces publication of long term results from Phase 3 VALOR study
TipRanks · 5d ago
Biogen Reports Long-Term QALSODY Data Showing Slowed SOD1-ALS Progression in Phase 3 Study
Reuters · 5d ago
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
Barchart · 5d ago
More
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Webull offers Biogen Inc stock information, including NASDAQ: BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.